Kodiak Sciences Inc (KOD)
Nasdaq: KOD · Biological Products, (No Diagnostic Substances) · Palo Alto, CA · filing with the SEC since 2009
Who owns Kodiak Sciences Inc
As filed with the SECHolders of 5% or more
5
Baker Bros. Advisors LP holds 35% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed Sep 30, 2026 says.
Directors and officers
13
report now, of 15 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Baker Bros. Advisors LP
SCHEDULE 13D/A · filed Sep 30, 2026 · Common Stock, $0.0001 par value per share · 32.8% in Dec 19, 2025
D. Victor Perlroth, M.D.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · 11% in Feb 14, 2025
Sirenia Capital Management LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.0001 per share
Blackrock, Inc.
SCHEDULE 13G · filed Apr 27, 2026 · Common Stock · 4.4% in Apr 29, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G · filed Aug 14, 2026 · COMMON STOCK
Point72 Asset Management, L.P.
SCHEDULE 13G · filed Apr 2, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 3.5% in Feb 17, 2026
What KOD reports owning in othersstakes of 5% or more, and other ties
3 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 31, 2026.
Insider tradesForm 4
14sales
88purchases
14sales on a scheduled plan
1people selling
$4.9Msold, in dollars
$241Mbought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 15 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Borgeson John A. | Chief Financial Officer | 14 | $4.9M | 14 | 0 | $0 |
| Baker Bros. Advisors (Gp) LLC | director | 0 | $0 | 0 | 30 | $58.6M |
| Baker Julian | director | 0 | $0 | 0 | 30 | $35.0M |
| 667, L.P. | director | 0 | $0 | 0 | 22 | $63.4M |
| Baker Bros. Advisors LP | director | 0 | $0 | 0 | 4 | $24.3M |
| Baker Brothers Life Sciences LP | director | 0 | $0 | 0 | 2 | $60.0M |